Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 0.41 |
| ▸ | VCP | P55072 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792984 | 1.00 | FBP1 (0.41) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL11034872 | 0.81 | FBP1 (0.50) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL1866963 | 0.79 | FBP1 (0.47) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL1866964 | 0.79 | FBP1 (0.47) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL17713675 | 0.79 | FBP1 (0.47) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL1363279 | 0.79 | FBP1 (0.47) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL1363276 | 0.79 | FBP1 (0.47) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL2491537 | 0.76 | NPC1 (0.40) | LMNA | |
| SCHEMBL2491542 | 0.76 | NPC1 (0.40) | LMNA | |
| SCHEMBL8138642 | 0.72 | FBP1 (0.48) | FBP1VCPLMNAEGFRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023108536-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| EP-2982368-A1 | Small molecule compounds displacing focal adhesion core components | Universität Konstanz (DE) | 2016-02-10 | — | — | EP | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20110046142-A1 | ANTIBIOTIC COMPOUNDS | NORTHEASTERN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2167074-A2 | ANTIBIOTIC COMPOUNDS | NorthEastern University (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156610-A2 | ANTIBIOTIC COMPOUNDS | NORTHEASTERN UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-0833630-A4 | NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE | SUGEN INC (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5763470-A | Benzopyran compounds and methods for their use | SUGEN INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0833630-A1 | NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE | Sugen, Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040110-A1 | NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5034381-A | Antagonist | CIBA-GEIGY CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0323807-A2 | Certain 2-substituted adenosine derivatives | CIBA-GEIGY AG (CH) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046142-A1 | ANTIBIOTIC COMPOUNDS | AADAC, SPOUT1, NRDC | FBP1 588/4885VCP 3212/4885LMNA 2276/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | FBP1 3141/4885VCP 3802/4885LMNA 974/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | FBP1 3141/4885VCP 3802/4885LMNA 974/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | FBP1 3141/4885VCP 3802/4885LMNA 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.